Virpax Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

VRPX Virpax Pharmaceuticals Inc

FDCFF Forum Energy Metals Corp

AFMD Affimed NV

ARVN Arvinas Inc

FOUR Shift4 Payments Inc

UK Ucommune International Ltd

CRDF Cardiff Oncology Inc

TRNR Interactive Strength Inc

OMGA Omega Therapeutics Inc

ACST Acasti Pharma Inc

Go

Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and drug delivery systems. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, PES200, AnQlar and NobrXiol. Probudur is a drug product candidate based on a liposomal delivery system utilizing large multi-vesicular vesicles (LMVVs) encapsulating a high dose of the local anesthetic bupivacaine. PES200 enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain for post-traumatic stress disorder. NobrXiol is being developed by Nanomerics as an investigational formulation delivered via the nasal route to enhance Cannabidiol transport to the brain.